---
layout: default
title: Nitric Oxide
parent: Model Prediction Only (L5)
nav_order: 652
evidence_level: L5
indication_count: 10
---

# Nitric Oxide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Nitric Oxide: From Inhaled Pulmonary Vasodilator Use to Malformation Syndrome with Odontal and/or Periodontal Component

## One-Sentence Summary

Nitric oxide is an inhaled gas used as a selective pulmonary vasodilator, and it is marketed in Canada under the brands INOMAX and KINOX.
The TxGNN model predicts it may be effective for **malformation syndrome with odontal and/or periodontal component**, but **0 clinical trials** and **20 publications** were retrieved, and none of the publications evaluates nitric oxide. This prediction rests on the model alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the Canadian licence data; the pack's context describes inhaled use for perioperative and neonatal pulmonary hypertension |
| Predicted New Indication | Malformation syndrome with odontal and/or periodontal component |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 2 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Nitric oxide is known as an inhaled vasodilator that lowers pulmonary vascular resistance without causing low blood pressure in the rest of the body. Its use is described in perioperative and neonatal pulmonary hypertension.

The prediction links this drug to a structural malformation syndrome affecting teeth and periodontal tissue. No credible mechanistic link was found. The high score (rank 8,341 in the model's ranking) is a graph-based inference only. The retrieved papers are generic periodontitis literature (guidelines, the diabetes association, plaque microbiology, surgical techniques), and none studies nitric oxide. An inhaled pulmonary vasodilator has no obvious biological rationale for a dental or periodontal developmental malformation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

The 20 retrieved publications all concern periodontitis in general. The 10 most relevant are listed below, and none evaluates nitric oxide.

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [35688447](https://pubmed.ncbi.nlm.nih.gov/35688447/) | 2022 | Guideline | J Clin Periodontol | EFP clinical practice guideline for treating stage IV periodontitis |
| [35420698](https://pubmed.ncbi.nlm.nih.gov/35420698/) | 2022 | Systematic Review | Cochrane Database Syst Rev | Periodontitis treatment for glycaemic control in people with diabetes |
| [29291254](https://pubmed.ncbi.nlm.nih.gov/29291254/) | 2018 | Cochrane review | Cochrane Database Syst Rev | Supportive periodontal therapy for maintaining the dentition after periodontitis treatment |
| [22057194](https://pubmed.ncbi.nlm.nih.gov/22057194/) | 2012 | Review | Diabetologia | Two-way relationship between periodontitis and diabetes |
| [38907216](https://pubmed.ncbi.nlm.nih.gov/38907216/) | 2024 | Review | J Nanobiotechnology | Biomaterial-mediated macrophage immunotherapy for periodontitis |
| [39233377](https://pubmed.ncbi.nlm.nih.gov/39233377/) | 2024 | Review | Periodontol 2000 | Association of sleep disorders, including obstructive sleep apnea, with periodontal health |
| [36883660](https://pubmed.ncbi.nlm.nih.gov/36883660/) | 2023 | Review | J Dent Res | Role of gingival fibroblasts in periodontitis pathogenesis |
| [20599785](https://pubmed.ncbi.nlm.nih.gov/20599785/) | 2010 | Review | Biochem Pharmacol | Complement overactivation and periodontal inflammation |
| [38362600](https://pubmed.ncbi.nlm.nih.gov/38362600/) | 2024 | Clinical study | J Dent Res | Effect of periodontitis and periodontal therapy on oral and gut microbiota (n=47) |
| [9495612](https://pubmed.ncbi.nlm.nih.gov/9495612/) | 1998 | Cohort | J Clin Periodontol | Microbial complexes in subgingival plaque (185 subjects) |

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2270846 | INOMAX |
| 2451328 | KINOX |

Dosage form and approved indication text are blank in the licence records.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction is an L5 model-only signal. It has no trials, no literature on nitric oxide, and no identifiable biological rationale, so it does not justify further investment.

Other candidates in the same evidence pack look more promising and may be worth reviewing instead:
- **Pulmonary arterial hypertension associated with congenital heart disease** (rank 8): the pack grades it L2 with "Proceed with Guardrails". It cites a completed Phase 3 trial of inhaled nitric oxide in Japan (NCT01959828, n=18) whose design is unconfirmed, plus recent literature on postoperative use.
- **Pulmonary arterial hypertension** (rank 7) and **pulmonary arteriovenous malformation** (rank 6): both carry a plausible mechanistic rationale but no Phase 3 evidence.

**To proceed, the following is needed:**
- Health Canada product monograph with warnings, contraindications and approved indications. This is a blocking gap for safety screening.
- Mechanism of action data from DrugBank.
- A decision on whether to re-focus the evaluation on the higher-evidence pulmonary indications.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

